Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Celcuity Inc.
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 26, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Inc. Announces $100 Million Private Placement
May 16, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
May 09, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
April 05, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
March 23, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
March 16, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
March 02, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
January 18, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
December 10, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
December 02, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
November 29, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
November 15, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
November 09, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
October 29, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
October 18, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
August 02, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in the William Blair Biotech Focus Conference
July 08, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Pricing of Follow-on Offering
June 28, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
CELC
Celcuity Announces Launch of Follow-on Offering
June 28, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
CELC
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
June 09, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
April 26, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
CELC
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
April 12, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit